Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company discontinued all clinical development of drugs in its autoimmune franchise and said it is evaluating internal options and strategic alternatives with the goal of maximizing value for its shareholders. Following the announcement, the firm removed clinical program revenue from its model and lowered its view of platform value to $50M, mostly related to the still-ongoing Sanofi (SNY) partnership for three early programs, from $500M, the analyst tells investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGMS:
- AMD downgraded, Nike upgraded: Wall Street’s top analyst calls
- IGM Biosciences price target lowered to $2 from $12 at Truist
- Morning Movers: Constellation Energy climbs following deal to buy Calpine
- IGM Biosciences downgraded to Neutral from Buy at Guggenheim
- IGM Biosciences downgraded to Sector Perform from Outperform at RBC Capital